Victory Capital Management Inc Aeglea Bio Therapeutics, Inc. Transaction History

Victory Capital Management Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 07, 2020	SELL	$4.01 - $11.04 $17,174 - $47,284	-4,283 Closed	0 $0
Q1 2020 May 04, 2020	SELL	$3.51 - $8.48 $294 - $712	-84 Reduced 1.92%	4,283 $20,000
Q4 2019 Feb 04, 2020	SELL	$7.23 - $8.55 $2,602 - $3,078	-360 Reduced 7.62%	4,367 $32,000
Q3 2019 Nov 12, 2019	BUY	$6.42 - $9.0 $30,347 - $42,543	4,727 New	4,727 $36,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.